Please assess the completion status of the following clinical trial:

Trial Title: Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Singleton pregnancy~* GDM diagnosed during pregnancy according to IADPSG criteria~* Self-monitoring of blood glucose~* After at least 7 days of dietary and lifestyle measures, unreached post-prandial glucose control~* 14-37 (+ 6 days) amenorrhea weeks at the time of randomization~* Signed informed consent~Exclusion Criteria:~* Prandial insulin use before randomization during this pregnancy~* Use of other oral hypoglycemic agents during this pregnancy~* Multiple pregnancy~* Known hepatic insufficiency~* Long time corticosteroid treatment~* Pre-existing diabetes in pregnancy~* Overt diabetes diagnosed during pregnancy (IADPSG criteria)~* Lack of Social Insurance~* Insufficient understanding~* Participant in another investigational drug study at inclusion visit~* Contraindications of acarbose~* Fetal malformation diagnosed by previous fetal ultrasound

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- acarbose (Type: EXPERIMENTAL): The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
- prandial insulin (Type: ACTIVE_COMPARATOR): The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.

Based on this trial design, predict the completion outcome and termination type (if applicable).